Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

Jian Song, Mark A. Knepper, Xinqun Hu, Joseph G. Verbalis and Carolyn A. Ecelbarger
Journal of Pharmacology and Experimental Therapeutics February 2004, 308 (2) 426-433; DOI: https://doi.org/10.1124/jpet.103.058008
Jian Song
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Knepper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinqun Hu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph G. Verbalis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn A. Ecelbarger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Synthetic agonists of the peroxisomal proliferator-activated receptor subtype γ (PPAR-γ) are highly beneficial in the treatment of type II diabetes. However, they are also associated with fluid retention and edema, potentially serious side effects of unknown origin. These studies were designed to test the hypothesis that rosiglitazone (RGZ, PPAR-γ agonist) may activate sodium- and water-reabsorptive processes in the kidney, possibly in response to a drop in mean arterial blood pressure (MAP), as well as directly through PPAR-γ. Targeted proteomics of the major renal sodium and water transporters and channel proteins was used to identify potentially regulated sites of renal sodium and water reabsorption. RGZ (47 or 94 mg/kg diet) was fed to male, Sprague-Dawley rats (∼270g) for 3 days. MAP, measured by radiotelemetry, was decreased significantly in rats fed either level of RGZ, relative to control rats. Delta MAP from baseline was –3.2 ± 1.2 mm Hg in rats fed high-dose RGZ versus + 3.4 ± 0.8 for rats fed control diet. RGZ did not affect feed or water intake, but rats treated with high-dose RGZ had decreased urine volume (by 22%), sodium excretion (44%), kidney weight (9%), and creatinine clearance (35%). RGZ increased whole kidney protein abundance of the α-1 subunit of Na-K-ATPase, the bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2), the sodium hydrogen exchanger (NHE3), the aquaporins 2 and 3, and endothelial nitric-oxide synthase. We conclude that both increases in renal tubule transporter abundance and a decrease in glomerular filtration rate likely contribute to the RGZ-induced sodium retention.

Footnotes

  • This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants KO1 DK02672 (to C.E. and J.S.) and RO1 DK38094 (to J.V. and M.S.), Georgetown University, the National Kidney Foundation George E. Schreiner, M.D. Young Investigator Award (to C.E.), a Research Award from the American Diabetes Association (to C.E. and J.S.), and the intramural budget of the National Heart, Lung, and Blood Institute (to M.K.).

  • DOI: 10.1124/jpet.103.058008.

  • ABBREVIATIONS: PPAR, peroxisomal proliferator-activated receptor; TZD, thiazolidinedione; NHE3, sodium hydrogen exchanger (type III), NaPi-2, sodium phosphate cotransporter (type II), ENaC, epithelial sodium channel; NCC, Na-Cl cotransporter; NKCC2, Na-K-2Cl cotransporter of the thick ascending limb; RGZ, rosiglitazone; NOx, nitrates plus nitrites; eNOS, endothelial nitric-oxide synthase; MAP, mean arterial blood pressure; GFR, glomerular filtration rate; AQP, aquaporin.

    • Received July 31, 2003.
    • Accepted October 24, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 308 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 308, Issue 2
1 Feb 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

Jian Song, Mark A. Knepper, Xinqun Hu, Joseph G. Verbalis and Carolyn A. Ecelbarger
Journal of Pharmacology and Experimental Therapeutics February 1, 2004, 308 (2) 426-433; DOI: https://doi.org/10.1124/jpet.103.058008

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

Jian Song, Mark A. Knepper, Xinqun Hu, Joseph G. Verbalis and Carolyn A. Ecelbarger
Journal of Pharmacology and Experimental Therapeutics February 1, 2004, 308 (2) 426-433; DOI: https://doi.org/10.1124/jpet.103.058008
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Knockout of Add3 Promotes L-NAME-Induced Renal Injury
  • Neuraminidase-1 Inhibition Therapy for Lung Fibrosis
  • GPER activation prevented the development of acute colitis
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics